An evidence-based review of skin cancer rates on biologic therapies

Development of Two Primary Malignant Melanomas after Treatment with Adalimumab: A Case Report and Review of the Possible Link between Biological Therapy with TNF-α Antagonists and Melanocytic Proliferation

(2010) A.C. Katoulis et al.   DERMATOLOGY

Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data

(2010) Johan Askling et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases

(2009) G R Burmester et al.   ANNALS OF THE RHEUMATIC DISEASES

Exacerbation of Undiagnosed Mycosis Fungoides During Treatment With Etanercept

(2009) Philippe Lafaille et al.   ARCHIVES OF DERMATOLOGY

Malignancy concerns with psoriasis treatments using phototherapy, methotrexate, cyclosporin, and biologics: facts and controversies

(2009) Luigi Naldi   CLINICS IN DERMATOLOGY

Long-term efficacy of biologics in dermatology

(2009) Leslie Castelo-Soccio et al.   Dermatologic Therapy

Prolongierte Psoriasistherapie mit TNF-α-Antagonisten

(2009) L. Kowalzick et al.   HAUTARZT

The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events

(2008) J P Leombruno et al.   ANNALS OF THE RHEUMATIC DISEASES

Hypopigmented T-cell dyscrasia evolving to hypopigmented mycosis fungoides during etanercept therapy

(2008) Gary S. Chuang et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Guidelines of care for the management of psoriasis and psoriatic arthritis

(2008) Alice Gottlieb et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY